Player Avatar zzlangerhans (99.85) Submitted: 12/19/2010 2:59:56 PM : Outperform Start Price: $11.98 NKTR Score: -56.54

Nektar's recent share price decline comes despite encouraging data for PEGylated irinotecan NKTR-102 in breast cancer and ovarian cancer. The pullback appears to be due to a rebalancing of demand as more conservative biotech investors depart now that the company has declared their intention of proceeding to phase III trials of NKTR-102 without a partner. For the long-term, sales are likely a better strategy than royalties as long as the company is able to manage their debt with a looming repayment deadline in 2012.

The GBMB is not a long-term strategy, so I wouldn't look at Nektar for a real-life buy unless the pullback continued into the single digits.

Featured Broker Partners